FDA Reclassification of Rapid Antigen Flu Testing

Clinical

Frederick S. Nolte, Ph.D., D(ABMM), F(AAM), shares his insight regarding the recent FDA reclassification of Rapid Antigen flu testing, and why it's an opportunity for lab leadership.

FDA Reclassification of Rapid Antigen Flu Testing

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Contributing Lab Leader

Frederick S. Nolte, PhD, D(ABMM), F(AAM)

Director of Clinical Laboratories

Medical University of South Carolina

FDA Reclassification of Rapid Antigen Flu Testing

FDA Reclassification of Rapid Antigen Flu Testing

Contributing Lab Leader

Other LabLeaders Clinical resources /

Other LabLeaders videos and webinars /